News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novian Health Wins Acclaim From Frost & Sullivan For Novilase Interstitial Laser Ablation Therapy For Early-Stage Malignant Breast Tumors


6/25/2014 9:24:02 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MOUNTAIN VIEW, Calif., Sept. 2, 2014 /PRNewswire/ -- Based on its recent analysis of the early-stage breast tumor treatment device market, Frost & Sullivan recognizes Novian Health, Inc. with the 2014 North America Frost & Sullivan Award for Technology Innovation Leadership. Novian Health has greatly improved the treatment of breast fibroadenoma and malignant tumors with its proprietary technology, Novilase® Laser Therapy. This innovative tool is a reliable, accurate, and easy-to-control ultrasound-guided thermo ablation device that performs minimally invasive surgery on breast tumors.

The procedure performed using Novilase leaves only two nicks, measuring approximately 0.3 cm in length and, unlike lumpectomies that result in substantial cosmetic damage, causes minimal scarring. Novilase is FDA 510(k) cleared and can ablate multiple fibroadenomas in a 30-minute outpatient procedure, allowing patients to return to their normal routine immediately. By eliminating the need for general anesthesia y, Novilase can potentially help patients save up to 30 percent of the costs they would have otherwise incurred during a traditional lumpectomy process.

"The major components of the Novilase system are the image-guided probes that enable the physician to target the exact location of the fibroadenoma or malignant tumor," said Frost & Sullivan Research Analyst Madhumitha Rangesa. "The temperature and laser delivery can be monitored in real time for optimal treatment results. The entire system is on a mobile cart that houses a Class IV laser source, in addition to disposable laser and thermal probes."

The probes are connected to a probe guide that varies the ablation radius if a smaller ablation zone is required. Once the probe is inserted into the malignant breast tumor or fibroadenoma, a fiber thread from the laser source is placed into the probe. A parallel temperature probe allows the physician to observe and control the temperature from the monitor. The tumor undergoes instantaneous cell death when the temperature at the periphery of the ablation zone reaches 60 degrees C; the cells will also die if the temperature is maintained over 51 degrees C for several minutes.

Over the course of several months following the procedure, the body's natural tissue healing process rebuilds the region where the tumor had been present. The technique results in minimal scarring, with no tissue loss since the breast tissue grows in uniformly covering the entire region that was ablated.

The laser ablation system is sized comparably to present-day ultrasound equipment and is portable to a large extent. This mobility encourages usage in rural areas, and can even be used by technicians with little training.

Significantly, Novian Health has proactively fostered strong relationships with regulatory bodies for its practice of documenting and validating its technology through multiple clinical trials. Additionally, its multicenter studies in the United States, France, and Great Britain will further validate the product, as having diverse populations undergo the Novilase Laser Therapy will result in a robust database of patient responses.

Novian Health has followed a strict patent application process and currently has 10 United States patents, 57 European patents (of which 27 are designs), and multiple international patents.

"In the future, once the Novilase procedure receives approval for treating malignant tumors, the company will have multiple collaborative options. The product can be released along with imaging products since imaging companies already have a strong foothold in the same sphere of diseases," noted Madhumitha. "Additionally, the company can collaborate with breast centers and clinics where breast tumor removal procedures are not commonly practiced."

Following the success of Novilase treatment for breast cancer, Novian Health is striving to extend its application to other types of cancers such as liver, skin, and prostate cancers. Overall, pursuing the necessary regulatory approvals and having established a strong IP portfolio, the company is now firmly entrenched as a technology leader in the breast cancer therapy market.

Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and customer value of new products and applications. The award lauds the high R&D spend on innovation, relevance to the industry, and positive impact on brand perception.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify industry best practices.

About Novian Health, Inc.

Novian Health Inc., based in Chicago with a subsidiary in Evry, France, is a privately held medical device company with proprietary technology for the treatment of tumors using Interstitial Laser Therapy. Developed as an alternative to surgery, the company's technology uses parametrically controlled heating for the ablation of tumors. Image-guided treatment of breast tumors is the first application of the technology, with the potential for Novilase to treat tumors elsewhere in the body. Novian Health has received U.S. FDA 510(k) clearance for the treatment of benign breast tumors. For more information, call (312) 266-7200 or access www.novianhealth.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion

Join Us: Join our community

Subscribe: Newsletter on "the next big thing"

Register: Gain access to visionary innovation

Contact:

Mireya Espinoza
P: 210.247.3870
F: 210.348.1003
E: mireya.espinoza@frost.com

Gene Bajorinas
P: 312.266.7205
E: ebajorinas@novianhealth.com

SOURCE Frost & Sullivan



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES